Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
5 search results for:

281 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-08-2022 | Non-small-cell lung cancer | News | Article

    ARROW update demonstrates first-line pralsetinib benefit for advanced RET fusion-positive NSCLC

    Overall, the median duration of treatment in the study was 7.9 months and the median dose intensity was 92%, with 7% of 281 patients discontinuing treatment due to pralsetinib-related AEs.

    Author:
    Lynda Williams
    Published in:
    Ann Oncol 2022; doi:10.1016/j.annonc.2022.08.002
  2. 17-12-2020 | Urothelial cancer | News | Article
    ESMO IO 2020

    ctDNA status linked to adjuvant atezolizumab benefit for muscle-invasive UC

    The current analysis involved 300 atezolizumab-treated patients, 39% of whom tested positive at baseline for ctDNA, and 281 patients who instead were under observation, 35% of whom were ctDNA-positive.

    Author:
    Lynda Williams
    Published in:
    ESMO Immuno-Oncology Virtual Congress 2020; 9–12 December
  3. 31-07-2020 | COVID-19 | News | Article

    Cancer diagnostic delays due to COVID-19 may lead to high excess mortality

    For breast cancer, the increase was 7.9–9.6% (281–344 additional deaths), for esophageal cancer the increase was estimated at 5.8–6.0% (330–342 additional deaths), and for lung cancer it was a 4.8–5.3% increase (1235–1372 additional deaths) up to 5 years after diagnosis.

    Author:
    Laura Cowen
    Published in:
    Lancet Oncol 2020; doi:10.1016/S1470-2045(20)30392-2 Lancet Oncol 2020; doi:10.1016/S1470-2045(20)30388-0 Lancet Oncol 2020; doi:10.1016/S1470-2045(20)30391-0
  4. 22-03-2019 | Castration-sensitive prostate cancer | News | Article

    Docetaxel add-on improves outcomes in high-risk localized prostate cancer

    By comparison, there were 59 deaths (23 from prostate cancer) among the 281 patients who received androgen suppression plus radiotherapy only.

    Published in:
    J Clin Oncol 2019; doi:10.1200/JCO.18.02158
  5. 21-03-2017 | Glioblastoma multiforme | News | Article

    Temozolomide improves short-course radiotherapy outcome in glioblastoma

    They were therefore randomly assigned to receive either short-course radiotherapy alone (40 Gy in 15 fractions over 3 weeks; n=281) or with concomitant and adjuvant temozolomide (75 mg/m 2 per day during radiotherapy and then up to 12 cycles of 150–200 mg/m 2 daily for 5 days of a 28-day cycle; n=281).

    Published in:
    N Engl J Med 2017; 376 : 1027–1037
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.